Pulse Biosciences, Inc.
$23.73
▼
-0.13%
2026-04-21 08:52:00
www.pulsebiosciences.com
NCM: PLSE
Explore Pulse Biosciences, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.61 B
Current Price
$23.73
52W High / Low
$26.3 / $12.56
Stock P/E
—
Book Value
$1.19
Dividend Yield
—
ROCE
-88.83%
ROE
-74.45%
Face Value
—
EPS
$-1.08
Exp Qtr EPS
—
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
116
Beta
1.69
Debt / Equity
9.34
Current Ratio
10.53
Quick Ratio
10.51
Forward P/E
-21.71
Price / Sales
3,626.73
Enterprise Value
$1.2 B
EV / EBITDA
-15.77
EV / Revenue
3,417.57
Rating
None
Target Price
$30
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | STAAR Surgical Company | $25.53 | — | $1.27 B | — | -11.99% | -21.7% | $30.81 / $15.59 | $6.97 |
| 2. | Bausch + Lomb Corporation | $16.76 | — | $5.94 B | — | 1.55% | -5.39% | $18.91 / $10.45 | $18.2 |
| 3. | Becton, Dickinson and Company | $155.63 | 25.5 | $44.7 B | 2.65% | 6.35% | 6.96% | $187.35 / $127.54 | $88.79 |
| 4. | DENTSPLY SIRONA Inc. | $12.79 | — | $2.61 B | 5.5% | 6.17% | -36.43% | $17.18 / $9.85 | $6.71 |
| 5. | West Pharmaceutical Services, Inc. | $274.81 | 40.51 | $19.81 B | 0.33% | 17.6% | 16.86% | $322.34 / $193.05 | $44.11 |
| 6. | Warby Parker Inc. | $25.89 | 1,889.51 | $3.1 B | — | -0.93% | 0.46% | $31 / $13.63 | $3 |
| 7. | Femasys Inc. | $0.42 | — | $25.6 M | — | -460.52% | -4.56% | $1.29 / $0.31 | $0.1 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.26 M | 0.09 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -18.25 M | -20.37 M | -20.27 M | -18.04 M | -20.26 M | — |
| Net Profit | -17.43 M | -19.39 M | -19.17 M | -16.8 M | -19.39 M | — |
| EPS in Rs | -0.26 | -0.29 | -0.28 | -0.25 | -0.29 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0.35 M | 0 M | 0 M | 0.7 M |
| Operating Profit | -76.94 M | -56.26 M | -43.57 M | -58.06 M |
| Net Profit | -72.78 M | -53.59 M | -42.21 M | -58.51 M |
| EPS in Rs | -1.07 | -0.79 | -0.62 | -0.86 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 94.54 M | 132.46 M | 59.15 M | 77.88 M |
| Total Liabilities | 13.88 M | 17.6 M | 14.79 M | 80.12 M |
| Equity | 80.66 M | 114.86 M | 44.36 M | -2.25 M |
| Current Assets | 83.42 M | 119.45 M | 45.33 M | 62.15 M |
| Current Liabilities | 7.92 M | 10.05 M | 6.71 M | 5.98 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -54.12 M | -36.34 M | -33.04 M | -47.01 M |
| Investing CF | -0.34 M | -0.12 M | -0.12 M | -0.4 M |
| Financing CF | 17.15 M | 110.14 M | 16.39 M | 79.94 M |
| Free CF | -54.46 M | -36.47 M | -33.16 M | -47.41 M |
| Capex | -0.34 M | -0.12 M | -0.12 M | -0.4 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | -100% | — | — |
| Earnings Growth % | -26.95% | 27.85% | — | — |
| Profit Margin % | — | — | -8357.86% | — |
| Operating Margin % | — | — | -8293.86% | — |
| Gross Margin % | — | — | -1606.29% | — |
| EBITDA Margin % | — | — | -8100.29% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.